Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.62 Analyst target: $15.50 Upside: 491.60%
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company is headquartered in Boulder, Colorado.
See the full interactive analysis & chart →Informational only — not investment advice.